Mimosa pudica Modulates Neuroactive Ligand-Receptor Interaction in Parkinson's Disease

被引:14
作者
Duyu, Taaza [1 ]
Khanal, Pukar [1 ]
Khatib, Nayeem Ashrafali [1 ]
Patil, Basanagouda Mahadevagouda [1 ]
机构
[1] KLE Acad Higher Educ & Res KAHER, KLE Coll Pharm, Dept Pharmacol & Toxicol, Belagavi 590010, Karnataka, India
关键词
Luteolin; Mimosa pudica; Network pharmacology; Parkinson's disease; Quercetin; IN-SILICO DOCKING; MANAGEMENT; DATABASE; TARGET;
D O I
10.5530/ijper.54.3.124
中图分类号
G40 [教育学];
学科分类号
040101 ; 120403 ;
摘要
Introduction: Mimosa pudica is scientifically reported for the enhancement of memory in multiple animal models including Parkinson's disease (PD); however, the probable molecular mechanism for this effect has not been explained yet. The present study demonstrates the probable molecular mechanism to improve memory via in silico techniques. Materials and Methods: Phytoconstituents present in M. pudica and their targets involved in Parkinson's disease were identified using open-source databases and published literature. Enrichment analysis of targeted proteins was identified using STRING, druglikeness of compounds was assessed using MolSoft and docking was carried using autodock4. Results: Out of twenty-seven phytoconstituents, seventeen modulated the proteins involved in the pathogenesis of PD. Norepinephrine was predicted to have the highest druglikeness score. The ADMET profiles revealed all phytoconstituents to be safe and are suitable for human consumption. Similarly, network analysis identified ADORA1 to be primarily targeted by phytoconstituents and luteolin was predicted to interact with maximum proteins. A docking study predicted quercetin and luteolin to possess the highest binding affinity with highly modulated protein ADORA1. Conclusion: M. pudica could primarily modulate neuroactive ligand receptor interaction followed by dopamine and serotonin synapses by regulating multiple proteins in PD.
引用
收藏
页码:732 / 739
页数:8
相关论文
共 36 条
[1]  
Ahmad Hafsa, 2012, Pharmacogn Rev, V6, P115, DOI 10.4103/0973-7847.99945
[2]  
Anderson Karen E, 2004, Dialogues Clin Neurosci, V6, P323
[3]   Adenosine receptors as drug targets - what are the challenges? [J].
Chen, Jiang-Fan ;
Eltzschig, Holger K. ;
Fredholm, Bertil B. .
NATURE REVIEWS DRUG DISCOVERY, 2013, 12 (04) :265-286
[4]  
DeMaagd George, 2015, P T, V40, P504
[5]   Current approaches to the treatment of Parkinson's Disease [J].
Ellis, J. Michael ;
Fell, Matthew J. .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2017, 27 (18) :4247-4255
[6]   Mechanism of Oxidative Stress in Neurodegeneration [J].
Gandhi, Sonia ;
Abramov, Andrey Y. .
OXIDATIVE MEDICINE AND CELLULAR LONGEVITY, 2012, 2012
[7]   Management of Parkinson's disease: Current and future pharmacotherapy [J].
Kakkar, Ashish Kumar ;
Dahiya, Neha .
EUROPEAN JOURNAL OF PHARMACOLOGY, 2015, 750 :74-81
[8]   KEGG: Kyoto Encyclopedia of Genes and Genomes [J].
Kanehisa, M ;
Goto, S .
NUCLEIC ACIDS RESEARCH, 2000, 28 (01) :27-30
[9]   In silico Antidiabetic Screening of Borapetoside C, Cordifolioside A and Magnoflorine [J].
Khanal, P. ;
Mandar, B. K. ;
Patil, B. M. ;
Hullatti, K. K. .
INDIAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2019, 81 (03) :550-+
[10]   In silico Docking Study of Limonoids from Azadirachta indica with pfpk5: A Novel Target for Plasmodium falciparum [J].
Khanal, P. ;
Mandar, B. K. ;
Magadum, Priyanka ;
Patil, B. M. ;
Hullatti, K. K. .
INDIAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2019, 81 (02) :326-332